In 2009, a very similar, negative report was published in JAMA claiming the long-term effect of minimally invasive prostatectomy was inferior to open surgery. Three years later, my good friend Dr. Quoc-Dien Trinh to totally crushed that myth. A similar fate looms for the doubters of robot-assisted gynecologic surgery.
Here's some history: In 1996, Lancet published a randomized, controlled trial on open versus laparoscopic cholecystectomy (gallbladder removal.) The study's conclusion: Open procedure was superior because there was no difference in hospital stay or recovery compared to "lap chole." Ten years later, surgeons are performing lap chole procedures as outpatient procedures and open cholecystectomy is thought of as medieval torture. Comparing surgical techniques is not like comparing two different pills. There is massive intra-surgeon heterogeneity even within the same procedures, which makes most surgical studies (including this JAMA paper) examinations of statistical noise.
I'm sure you've noticed lawyers love litigation. Intuitive Surgical has deep pockets, so I'm not surprised in the least that the company is now wearing a target on its back. You can whine about the company's over-the-top marketing, its bullying salespeople and its heavily financed surgeon spokespeople. Despite all that, the doctors I admire most in my field -- and who get no Intuitive Surgical money -- have all adopted robotics in their surgical practices. Why? Because it's a transformative surgical approach that benefits our patients -- decreased blood loss, less pain, shorter hospital stays and fewer complications. When other fields begin to understand and learn the technology, I have no doubt they will find similar success.
Disclosure: Davies doesn't own Intuitive Surgical stock and has never been compensated by the company in any way.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts